EXACT Sciences (EXAS) to Release Earnings on Thursday

EXACT Sciences (NASDAQ:EXAS) is scheduled to be releasing its earnings data after the market closes on Thursday, February 22nd. Analysts expect EXACT Sciences to post earnings of ($0.29) per share for the quarter.

EXACT Sciences (EXAS) opened at $49.08 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98. The firm has a market cap of $5,880.00, a PE ratio of -42.68 and a beta of 0.58. EXACT Sciences has a 52 week low of $18.50 and a 52 week high of $63.60.

In other EXACT Sciences news, insider Graham Peter Lidgard sold 45,770 shares of EXACT Sciences stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $58.27, for a total transaction of $2,667,017.90. Following the completion of the sale, the insider now directly owns 237,820 shares in the company, valued at $13,857,771.40. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kevin T. Conroy sold 134,057 shares of EXACT Sciences stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total transaction of $7,976,391.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 764,182 shares of company stock valued at $40,574,047. 4.00% of the stock is owned by company insiders.

Several research firms have recently weighed in on EXAS. Leerink Swann reissued an “outperform” rating and issued a $67.00 price target (up from $63.00) on shares of EXACT Sciences in a research note on Monday, November 13th. Robert W. Baird downgraded shares of EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 price target on the stock. in a research note on Monday, November 13th. Bank of America raised their price objective on shares of EXACT Sciences from $58.00 to $67.00 and gave the stock a “buy” rating in a research report on Wednesday, November 29th. Zacks Investment Research cut shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Finally, BTIG Research cut shares of EXACT Sciences from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 1st. Eight research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. EXACT Sciences currently has a consensus rating of “Buy” and a consensus price target of $52.84.

WARNING: “EXACT Sciences (EXAS) to Release Earnings on Thursday” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/15/exact-sciences-exas-to-release-earnings-on-thursday.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Earnings History for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply